Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase1a, Randomized Placebo-controlled, Single and Multiple Dose, Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Oral NNI-362 in Healthy Aged Volunteers 50 to 72 Years of Age

NCT04074837 is registered in ClinicalTrials.gov with Neuronascent, Inc. as lead sponsor.

NCT NCT04074837
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04074837 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase1a, Randomized Placebo-controlled, Single and Multiple Dose, Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Oral NNI-362 in Healthy Aged Volunteers 50 to 72 Years of Age
Lead sponsor
Neuronascent, Inc.
Phase
Phase 1
Overall status
Completed
Start date
August 1, 2019
Completion date
August 15, 2021
Enrollment
56 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer disease